Did The US Jump The Gun With The New Omicron-Targeted Vaccines?
Op-ed calls for more information about cost versus benefit as vaccine-makers prepare to hike prices.
By Céline Gounder and Elisabeth Rosenthal
Op-ed calls for more information about cost versus benefit as vaccine-makers prepare to hike prices.